



# KOTHARI PHYTOCHEMICALS & INDUSTRIES LTD.

CIN : L15491WB1897PLC001365

Phone : 91-33-2230-2331/6  
91-33-2230-4184  
~~91-33-2242-6189~~  
E-mail : hokothari@yahoo.com



REGD. OFFICE :  
C-4, GILLANDER HOUSE  
8, NETAJI SUBHAS ROAD  
KOLKATA-700 001  
INDIA

Ref.: KPIL / 2018 - 19 / CSE/32

May 30, 2018

The Secretary  
The Calcutta Stock Exchange Limited  
7, Lyons Range  
KOLKATA - 700 001

Dear Sir,

**Sub. : Audited Financial Results for the Quarter and Year ended 31<sup>st</sup> May, 2018.**

**CSE Stock Code : Physical - 21160 & Demat - 10021160**

**ISIN : INE264E01016**

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), please find enclosed herewith a copy of the Audited Financial Results of the Company alongwith Balance Sheet and Segment - wise Revenue, Results, Assets & Liabilities, prepared in accordance with Ind - AS adopted for the first time, for the Quarter and Year ended 31<sup>st</sup> March, 2018 as reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on today i.e. 30<sup>th</sup> May, 2018.

**FURTHER** also find enclosed copy of the Independent Auditor's Report dated 30<sup>th</sup> May, 2018 on the Audited Financial Results of the Company for the Quarter and Year ended 31<sup>st</sup> March, 2018, given by the statutory auditors of the Company K. Ray & Company, Chartered Accountants.

**FURTHER** pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of Extract of Unaudited Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2018 to be published in the newspapers as per above said Regulation.


**FURTHER** also find enclosed a declaration under Regulation 33 (3) (d) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR) in respect of unmodified Auditor's Report on Audited Financial Results of the Company for the year ended 31<sup>st</sup> March, 2018.

Please take the above on your record.



Thanking you,

Yours faithfully,

For **KOTHARI PHYTOCHEMICALS & INDUSTRIES LTD.**

  
**M. L. Daga**  
(FCS - 2650)  
Company Secretary cum Compliance Officer

Encl.: As above

	The Calcutta Stock Exchange Limited Listing Department Received Contents not verified
Sl. No. 21	Dated 30/5/18
Signature 	



( ₹ in lakh )

**Statement of Audited Financial Results for the Quarter and Year Ended on 31st March, 2018.**

Sl. No.	Particulars	Quarter Ended			Year Ended	
		31-03-2018	31-12-2017	31-03-2017	31-03-2018	31-03-2017
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
<b>1. Income</b>						
(a) Revenue from Operations		719.78	514.40	465.76	2,400.09	2,120.55
(b) Other Income		49.40	92.14	91.11	238.48	214.61
<b>Total income</b>		<b>769.18</b>	<b>606.54</b>	<b>556.87</b>	<b>2,638.57</b>	<b>2,335.16</b>
<b>2. Expenses</b>						
(a) Cost of Materials consumed		259.47	248.82	268.95	973.98	771.66
(b) Purchase of Stock - in - trade		-	-	-	114.24	-
(c) Changes in inventories of finished goods, work - in - progress and stock - in - trade		136.45	32.71	(102.87)	89.23	239.44
(d) Excise Duty		-	-	23.38	19.23	84.13
(e) Employee benefits expense		93.39	78.20	84.34	315.97	283.76
(f) Finance costs		0.49	1.86	6.12	6.82	11.99
(g) Depreciation and amortisation expense		21.60	23.46	15.71	91.98	85.98
(h) Power and fuel		31.68	28.96	16.77	113.64	87.44
(i) Other expenditure		100.62	49.74	45.65	275.40	241.45
<b>Total expenses</b>		<b>643.70</b>	<b>463.75</b>	<b>358.05</b>	<b>2,000.49</b>	<b>1,805.85</b>
<b>3. Profit / (Loss) before exceptional Items and Tax (1-2)</b>		<b>125.48</b>	<b>142.79</b>	<b>198.82</b>	<b>638.08</b>	<b>529.31</b>
<b>4. Exceptional Items</b>		-	-	-	-	-
<b>5. Profit / (Loss) before Tax from continuing operations (3-4)</b>		<b>125.48</b>	<b>142.79</b>	<b>198.82</b>	<b>638.08</b>	<b>529.31</b>
<b>6. Tax expense</b>		<b>38.80</b>	<b>34.00</b>	<b>55.23</b>	<b>178.80</b>	<b>147.23</b>
<b>7. Net Profit / (Loss) for the period from continuing operations (5-6)</b>		<b>86.68</b>	<b>108.79</b>	<b>143.59</b>	<b>459.28</b>	<b>382.08</b>
<b>8. Profit / (Loss) before Tax from discontinued operations</b>		<b>(33.17)</b>	<b>446.35</b>	<b>(5.32)</b>	<b>401.90</b>	<b>3.91</b>
<b>9. Tax expenses / (credit) of discontinued operations</b>		<b>58.00</b>	<b>32.00</b>	<b>(1.70)</b>	<b>86.00</b>	<b>1.30</b>
<b>10. Net Profit / (Loss) from discontinued operations (8-9)</b>		<b>(91.17)</b>	<b>414.35</b>	<b>(3.62)</b>	<b>315.90</b>	<b>2.61</b>
<b>11. Profit / (Loss) for the period (7+10)</b>		<b>(4.49)</b>	<b>523.14</b>	<b>139.97</b>	<b>775.18</b>	<b>384.69</b>
<b>12. Other Comprehensive Income not to be reclassified to Profit and Loss in subsequent periods (net of tax)</b>		<b>2.12</b>	<b>-</b>	<b>(0.06)</b>	<b>2.12</b>	<b>(0.06)</b>
<b>13. Total Comprehensive Income for the period (11+12)</b>		<b>(2.37)</b>	<b>523.14</b>	<b>139.91</b>	<b>777.30</b>	<b>384.63</b>
<b>14. Paid - up equity share capital (Face Value of ₹ 10/- each)</b>		<b>388.32</b>	<b>388.32</b>	<b>388.32</b>	<b>388.32</b>	<b>388.32</b>
<b>15. Earnings / (Loss) per Equity Share of Face Value of ₹ 10/- each (not annualised) :</b>						
For Continuing Operations :						
Basic and Diluted		2.23	2.80	3.70	11.83	9.84
For Discontinued Operations :						
Basic and Diluted		(2.35)	10.67	(0.09)	8.14	0.07
For Continuing and Discontinued Operations :						
Basic and Diluted		(0.12)	13.47	3.61	19.97	9.91

**Balance Sheet.**

( ₹ in lakh )

Particulars	As at	As at	As at
	31-03-2018	31-03-2017	01-04-2016
	(Audited)	(Audited)	(Audited)
<b>ASSETS</b>			
<b>1 Non - Current Assets</b>			
(a) Property, Plant and Equipment	603.98	589.01	628.74
(b) Intangible Assets	0.56	-	-
(c) Capital Work - in - Progress	306.98	368.62	378.21
(d) Investments in Associates	517.49	517.49	517.49
(e) Financial Assets			
(i) Investments	1,234.48	895.20	829.39
(ii) Other Financial Assets	20.51	27.89	26.25
(f) Other Non - Current Assets	9.07	8.87	23.12
<b>Sub - total - Non - Current Assets</b>	<b>2,693.07</b>	<b>2,407.08</b>	<b>2,403.20</b>





<b>2 Current Assets</b>			
(a) Inventories	618.99	977.17	1,011.45
(b) Financial Assets			
(i) Trade Receivables	127.44	157.62	124.29
(ii) Cash and Cash Equivalents	261.02	75.01	499.73
(iii) Bank Balances other than (ii) above	676.57	491.87	148.22
(iv) Loans	1,000.00	950.00	350.00
(v) Other Financial Assets	27.65	26.87	0.90
(c) Current Tax Assets (Net)	43.68	88.29	118.93
(d) Other Current Assets	57.35	87.35	120.81
	2,812.70	2,854.18	2,374.33
Assets pertaining to Discontinued Operations	-	-	-
<b>Sub - total - Current Assets</b>	<b>2,812.70</b>	<b>2,854.18</b>	<b>2,374.33</b>
<b>TOTAL - ASSETS</b>	<b>5,505.77</b>	<b>5,261.26</b>	<b>4,777.53</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
(a) Equity Share Capital	388.32	388.32	388.32
(b) Other Equity	4,792.15	4,155.06	3,887.27
<b>Sub - total - Equity</b>	<b>5,180.47</b>	<b>4,543.38</b>	<b>4,275.59</b>
<b>LIABILITIES</b>			
<b>1. Non - Current Liabilities</b>			
(a) Provisions	34.24	24.32	18.91
(b) Deferred Tax Liabilities (Net)	58.45	25.59	24.94
<b>Sub - total - Non - Current Liabilities</b>	<b>92.69</b>	<b>49.91</b>	<b>43.85</b>
<b>2. Current liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings	-	300.00	246.74
(ii) Trade Payables	181.36	120.82	157.97
(iii) Other Financial Liabilities	46.38	64.09	47.00
(b) Current Tax Liabilities	-	-	-
(c) Other Current Liabilities	4.87	183.06	6.38
	232.61	667.97	458.09
Liabilities pertaining to Discontinued Operations	-	-	-
<b>Sub - total - Current Liabilities</b>	<b>232.61</b>	<b>667.97</b>	<b>458.09</b>
<b>TOTAL - LIABILITIES</b>	<b>325.30</b>	<b>717.88</b>	<b>501.94</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>5,505.77</b>	<b>5,261.26</b>	<b>4,777.53</b>

**Audited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Year Ended on 31st March, 2018**

( ₹ in lakh )

Particulars	Quarter Ended			Year Ended	
	31-03-2018 (Audited)	31-12-2017 (Unaudited)	31-03-2017 (Audited)	31-03-2018 (Audited)	31-03-2017 (Audited)
<b>1. Segment Revenue</b>					
<b>A) Continuing Operations :</b>					
(a) Bulk Drugs	512.11	343.52	184.31	1,666.88	1,242.50
(b) Chemicals	207.67	170.88	281.44	733.21	878.05
(c) Unallocated	-	-	-	-	-
<b>Total</b>	<b>719.78</b>	<b>514.40</b>	<b>465.75</b>	<b>2,400.09</b>	<b>2,120.55</b>
<b>Less: Inter Segment Revenue</b>	-	-	-	-	-
<b>Net Sales / Income from Continuing Operations</b>	<b>719.78</b>	<b>514.40</b>	<b>465.75</b>	<b>2,400.09</b>	<b>2,120.55</b>
<b>B) Net Sales / Income from Discontinued Operations (Chemicals)</b>	<b>0.00</b>	<b>-</b>	<b>16.39</b>	<b>14.05</b>	<b>105.78</b>
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment)</b>					
<b>A) Continuing Operations :</b>					
(a) Bulk Drugs	140.21	66.60	100.21	538.25	375.77
(b) Chemicals	23.20	20.00	49.06	61.33	90.98
(c) Unallocated	(15.85)	81.52	71.29	137.29	160.44
<b>Total</b>	<b>147.56</b>	<b>168.12</b>	<b>220.56</b>	<b>736.87</b>	<b>627.19</b>
<b>Less: i) Finance Costs</b>	<b>0.49</b>	<b>1.86</b>	<b>6.12</b>	<b>6.82</b>	<b>11.99</b>
<b>ii) Other Un-allocable Expenditure net off unallocable income</b>	<b>21.59</b>	<b>23.47</b>	<b>15.62</b>	<b>91.97</b>	<b>85.89</b>
<b>Total Profit / (Loss) Before Tax from Continuing Operations</b>	<b>125.48</b>	<b>142.79</b>	<b>198.82</b>	<b>638.08</b>	<b>529.31</b>
<b>B) Total Profit / (Loss) from Discontinued Operations (Chemicals)</b>	<b>(33.17)</b>	<b>446.35</b>	<b>(5.32)</b>	<b>401.90</b>	<b>3.91</b>





<b>3. Segment Assets</b>					
(a) Bulk Drugs	2,146.11	2,132.58	2,210.25	2,146.11	2,210.25
(b) Chemicals	428.59	406.12	540.63	428.59	540.63
(c) Unallocated	2,931.08	2,981.21	2,510.38	2,931.08	2,510.38
<b>Total Segment Assets</b>	<b>5,505.77</b>	<b>5,519.91</b>	<b>5,261.26</b>	<b>5,505.77</b>	<b>5,261.26</b>
<b>4. Segment Liabilities</b>					
(a) Bulk Drugs	98.84	154.81	314.85	98.84	314.85
(b) Chemicals	122.84	125.24	126.08	122.84	126.08
(c) Unallocated	103.62	51.58	276.95	103.62	276.95
<b>Total Segment Liabilities</b>	<b>325.30</b>	<b>331.63</b>	<b>717.88</b>	<b>325.30</b>	<b>717.88</b>

- Notes
- The above Audited Financial Results and Segment Results for the Quarter / Year ended 31st March, 2018 were reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 30th May, 2018.
  - The Board of Directors have recommended dividend of ₹ 3/- Per Ordinary Share i. e. 30 % on the face value of ₹ 10/- each subject to approval of the shareholders.
  - The figures for the quarter ended 31st March, 2018 are the balancing figure between Audited figure in respect of the full financial year and published year to date figures upto third quarter of the relevant financial year.
  - The Company has adopted Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, from April 1, 2016 being the date of transition as per Ind AS 101.
  - Tax expenses / (credit) include deferred tax.
  - The Company has discontinued the operation of its Southern Synthetics Division during the quarter ended 30th September, 2017. Income and other expenses of this Division has been disclosed as are required as per Ind AS.
  - During the Quarter / Year under Review, the assets relating to Southern Synthetics Division of the Company have been sold / disposed off. Net gain on such sale / disposal has been included under "Net Profit, / (Loss) from discontinued operations" as shown in item 10 above.
  - The reconciliation of net profit in accordance with Indian GAAP (referred to as "Previous GAAP") to total comprehensive income in accordance with Ind AS is as under :

Particulars	( ₹ in lakh )	
	Quarter ended 31.03.2017	Year ended 31.03.2017
Net Profit as per Previous Indian GAAP	95.46	303.99
Add / (Less) : Adjustment on account of :		
Fair Valuation of Financial Assets	46.69	82.82
Provision for Expected Credit Losses on Trade Receivable	(0.26)	(0.20)
Remeasurement Cost of Net Defined Benefit Liability	(2.76)	(2.76)
Tax effect on above adjustments	0.84	0.84
<b>Net Profit as per Ind AS</b>	<b>139.97</b>	<b>384.69</b>
Other Comprehensive Income (Net of Tax)	(0.06)	(0.06)
<b>Total Comprehensive Income for the period</b>	<b>139.91</b>	<b>384.63</b>


- Post applicability of Goods and Service Tax (GST) w. e. f. July 1, 2017. Revenue from operations is disclosed net of GST. However, revenue for the period upto June 30, 2017 is inclusive of Excise duty. Accordingly, revenue from operations and other expenses for the quarter / year ended March 31, 2018 not comparable with the previous periods presented in the results.
- Reconciliation of total equity as previously reported on account of transition from the previous Indian GAAP (referred to as "Previous GAAP") to Ind AS for the year ended 31st March, 2017.

Particulars	( ₹ in lakh )	
	Year ended 31.03.2017	
Total Equity (Shareholder's Funds) under Previous Indian GAAP	4,133.81	
Add / (Less) : Adjustment on account of :		
Fair Valuation of Financial Assets	275.39	
Provision for Expected Credit Losses on Trade Receivable	(0.59)	
Remeasurement Cost of Net Defined Benefit Liability	(2.85)	
Tax effect on above adjustments	(2.59)	
Reversal of Proposed Dividend and Tax thereon	140.21	
<b>Total Equity under Ind AS</b>	<b>4,543.38</b>	

- Tax provision for the year ended 31st March, 2018 has been made under section 115JB of the Income Tax Act 1961 as Minimum Alternate Tax (MAT).
- The results of the Company are available at [www.cse-india.com](http://www.cse-india.com) and [www.kothariphyto.com](http://www.kothariphyto.com).
- Previous period's figures have been regrouped / rearranged wherever necessary to conform to the current period's classification.

Place **Kolkata**  
Date **30th May, 2018**



  
**A. K. TOSHNIWAL**  
Managing Director  
(DIN : 06872891)





## REVIEW REPORT TO

### THE BOARD OF DIRECTORS OF KOTHARI PHYTOCHEMICALS & INDUSTRIES LIMITED

1. We have audited the accompanying Statement of Financial Results of **KOTHARI PHYTOCHEMICALS & INDUSTRIES LIMITED** ("the Company"), for the Quarter and Year ended 31<sup>st</sup> March, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR / CFD / FAC / 62 / 2016 dated 5<sup>th</sup> July, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our audit of such financial statements.

2. The reports of audit of Phytochemicals Division and Claro India Division carried out by Jitendra K Agarwal & Associates have been taken into account for the purpose of preparing our report.
3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. This Standard requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance as to whether the Statement is free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:



Contd. .... P / 2




- (a) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR / CFD / FAC / 62 / 2016 dated July 5, 2016; and
- (b) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and Total comprehensive income and other financial information of the Company for the year ended March 31, 2018.
5. The Statement includes the results for the Quarter ended March 31, 2018 being the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.
6. The previously issued financial information of the Company for the quarter ended March 31, 2017 prepared in accordance the Companies (Accounting Standards) Rules, 2006 and audited by the predecessor auditor (whose report expressed an unmodified opinion) have been restated to comply with Ind AS and included in this Statement as comparative financial information. Adjustments made to the previously issued financial information prepared in accordance with the Companies (Accounting Standards) Rules, 2006 to comply with Ind AS have been audited by us.

The comparative financial information of the Company for the year ended March 31, 2017 included in this Statement are based on the statutory financial statements prepared in accordance with the Companies (Accounting Standards) Rules, 2006 audited by the predecessor auditor whose report for the year ended March 31, 2017 expressed an unmodified opinion on those financial statements, and have been restated to comply with Ind AS. Adjustments made to the previously issued said financial information prepared in accordance with the Companies (Accounting Standards) Rules, 2006 to comply with Ind AS have been audited by us.

Our report is not modified in respect of these matters.

For **K. RAY & COMPANY**  
Chartered Accountants  
(Firm's Registration No. 312142E)



Supratim Roychoudhury  
Partner

Membership No.: 066040

Kolkata, 30<sup>th</sup> May, 2018







# KOTHARI PHYTOCHEMICALS & INDUSTRIES LIMITED

CIN : L15491WB1897PLC001366

Regd. Office : C - 4, Gillander House, 8 Netaji Subhas Road, Kolkata - 700 001

Phone : 2230 - 2331 (6 lines), E.mail : hokothari@yahoo.com

Website : www.kothariphyto.com

## Extract of Audited Financial Results for the Quarter and Year Ended 31st March, 2018

(₹ in lakh)

Sl. No.	Particulars	Quarter Ended			Year Ended	
		31-03-2018	31-12-2017	31-03-2017	31-03-2018	31-03-2017
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1.	Total Income from Operations	769.18	606.54	556.87	2638.57	2335.16
2.	Net Profit for the period (before Tax, Exceptional and / or Extraordinary items)	125.48	142.79	198.82	638.08	529.31
3.	Net Profit for the period before tax (after Exceptional and / or Extraordinary items)	125.48	142.79	198.82	638.08	529.31
4.	Net Profit for the period after tax (after Exceptional and/ or Extraordinary items)	86.68	108.79	143.59	459.28	382.08
5.	Net Profit / (Loss) from discontinued operations	(91.17)	414.35	(3.62)	315.90	2.61
6.	Other comprehensive Income (net of tax)	2.12	-	(0.06)	2.12	(0.06)
7.	Total Comprehensive Income for the period	(2.37)	523.14	139.91	777.30	384.63
8.	Equity Share Capital (Face value Rs. 10/- each)	388.32	388.32	388.32	388.32	388.32
9.	Earnings Per Equity Share (of Rs. 10/- each) (not annualised) :					
	For Continuing Operations :					
	Basic and Diluted	2.23	2.80	3.70	11.83	9.84
	For Discontinued Operations :					
	Basic and Diluted	(2.35)	10.67	(0.09)	8.14	0.07
	For Continuing and Discontinued Operations :					
	Basic and Diluted	(0.12)	13.47	3.61	19.97	9.91

### Notes:

- The above is an extract of the detailed format of Quarterly and Year ended Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Year ended Audited Financial Results are available on the Calcutta Stock Exchange website (www.cse-india.com) and on the Company's website (www.kothariphyto.com).
- The Company has adopted Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder, from April 1, 2016 being the date of transition as per Ind AS 101.
- The Company has discontinued the operation of its Southern Synthetics Division during the quarter ended 30th September, 2017. Income and other expenses of this Division has been disclosed as are required as per Ind AS.
- During the Quarter / Year under Review, the assets relating to Southern Synthetics Division of the Company have been sold / disposed off. Net gain on such sale / disposal has been included under "Net Profit, / (Loss) from discontinued operations" as shown in item 5 above.
- The reconciliation of net profit in accordance with Indian GAAP (referred to as "Previous GAAP") to total comprehensive income in accordance with Ind AS is as under:

Particulars	Quarter ended	
	31-03-2017	31-03-2017
Net Profit as per Previous Indian Gaap	95.46	303.99
Add / (Less) : Adjustment on account of :		
Fair Valuation of Financial Assets	46.69	82.82
Provision for Expected Credit Losses on Trade Receivables	(0.26)	(0.20)
Remeasurement Cost of Net Defined Benefit Liability	(2.76)	(2.76)
Tax effect on above adjustments	0.84	0.84
<b>Net Profit as per Ind AS</b>	<b>139.97</b>	<b>384.69</b>
Other Comprehensive Income (Net of Tax)	(0.06)	(0.06)
<b>Total Comprehensive Income for the period</b>	<b>139.91</b>	<b>384.63</b>

- Previous period's figures have been regrouped / rearranged wherever necessary to conform to the current period's classification.

By order of the Board  
For Kothari Phytochemicals & Industries Limited

A. K. TOSHNIWAL  
Managing Director  
(DIN : 06872891)

Place : Kolkata  
Date : 30th May, 2018



Ref.: KPIL / 2018 – 19 / CSE/33

May 30, 2018

The Secretary  
The Calcutta Stock Exchange Limited  
7, Lyons Range  
KOLKATA – 700 001

Dear Sir,

**Sub.: Declaration pursuant to Regulation 33 (3) (d) of the Securities Exchange Board of India (LODR) (Amendment) Regulations, 2017.**

**CSE Stock Code : Physical – 21160 & Demat - 10021160**  
**ISIN : INE264E01016**

We hereby declare that the Statutory Auditors of the Company, K. Ray & Company, Chartered Accountants (FRN – 312142E) have issued an Audit Report with unmodified opinion on the audited financial results of the Company for financial year ended on 31<sup>st</sup> March, 2018.

This declaration is issued in compliance with Regulation 33 (3) (d) of the SEBI (LODR) (Amendment) Regulations, 2016.

Thanking you,

Yours faithfully,  
For **KOTHARI PHYTOCHEMICALS & INDUSTRIES LTD.**

  
**A. K. Toshniwal**  
Managing Director  
(DIN : 06872891)